Nucleoside transport-deficient mutants of PK-15 pig kidney cell line.
Previous studies indicated that PK-15 pig kidney cells express solely a nitrobenzylthioinosine-sensitive, equilibrative nucleoside transporter. In the present study, PK-15 cells were mutagenized by treatment with ICR-170 and nucleoside transport-deficient mutants selected in a single step in growth medium containing tubercidin and cytosine arabinoside at a frequency of about 2 x 10(6). The mutants were simultaneously at least 100-times more resistant to tubercidin, cytosine arabinoside and 5-fluorodeoxyuridine than the wild-type parent cells. The mutants failed to transport thymidine and uridine and had lost all high affinity nitrobenzylthioinosine binding sites. Residual low level uptake of thymidine by the mutants was shown to be due to nonmediated permeation (passive diffusion), which explains the sensitivity of the mutants to growth inhibition by high concentrations of the nucleoside drugs. Passive diffusion of thymidine at a concentration of 16 microM was not rapid enough to support the growth of nucleoside transport-deficient mutant cells that had been made thymidine-dependent by treatment with methotrexate, whereas wild-type cells grew normally under these conditions. The nucleoside transport-deficient mutants exhibited about the same growth rate and plating efficiency (60-80%) as wild-type cells, but formed larger colonies than wild-type cells because of a more extensive spread of the cells on the surface of culture dishes. PK-15 cells adhere very strongly to the surface of culture dishes and have been transformed with high efficiency with plasmid DNA either via lipofection or electroporation.
Aran
J M
JM
Department of Microbiology, University of Minnesota Medical School, Minneapolis 55455-0312.
Plagemann
P G
PG
D000818:Animals; D001692:Biological Transport / Q000235:genetics; D002352:Carrier Proteins / Q000235:genetics* / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002999:Clone Cells; D003561:Cytarabine / Q000494:pharmacology; D004247:DNA / Q000235:genetics / Q000378:metabolism; D004926:Escherichia coli / Q000235:genetics; D005434:Flow Cytometry; D005467:Floxuridine / Q000494:pharmacology; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000378:metabolism / Q000494:pharmacology; D007668:Kidney; D007700:Kinetics; D008565:Membrane Proteins / Q000235:genetics* / Q000378:metabolism*; D008727:Methotrexate / Q000494:pharmacology; D009154:Mutation; D033703:Nucleoside Transport Proteins; D009705:Nucleosides / Q000378:metabolism*; D010957:Plasmids; D011994:Recombinant Proteins / Q000378:metabolism; D013552:Swine; D013936:Thymidine / Q000378:metabolism; D014162:Transfection; D014372:Tubercidin / Q000494:pharmacology; D014529:Uridine / Q000378:metabolism
D002352:Carrier Proteins; D007042:Hypoxanthines; D008565:Membrane Proteins; D033703:Nucleoside Transport Proteins; D009705:Nucleosides; D011994:Recombinant Proteins; D005467:Floxuridine; D003561:Cytarabine; D019271:Hypoxanthine; D004247:DNA; D014372:Tubercidin; D013936:Thymidine; D014529:Uridine; D008727:Methotrexate